Simble Solutions Partners with Macquarie University to Advance Nanosensor Technology

Simble is betting big on unproven tech while burning cash and facing survival risks.

What the company is saying

Simble Solutions is positioning itself as an innovator in nanosensor technology, emphasizing a two-year co-funded research collaboration with Macquarie University as a transformative step. The company wants investors to believe that this partnership will accelerate the development of exclusive nanosensor applications, with initial targets in e-skin for robotics, UV dosimetry, and health monitoring, and future expansion into broader sectors like safety and environmental monitoring. The announcement frames the $288,000 research contribution and the conditional acquisition of Next Nano as strategic investments that will enable Simble to integrate proprietary hardware into its SimbleSense and CarbonView platforms, aiming to reduce reliance on third-party devices and improve margins. The language used is aspirational, highlighting 'exclusive commercialisation rights' and a 'pathway to expand' into new markets, but it stops short of providing concrete milestones or timelines for these outcomes. Prominently, the announcement details the capital raise of $2.65 million at $0.005 per share, presenting it as a vote of confidence in the company's direction. However, the report also openly acknowledges a material uncertainty regarding Simble's ability to continue as a going concern, citing ongoing losses and liquidity constraints. The tone is neutral and measured, with management projecting cautious optimism but also disclosing significant risks. Professor Noushin Nasiri is named as Macquarie's Chief Investigator, lending academic credibility to the research, but no notable institutional investors or industry leaders are identified as backers. Overall, the narrative fits a classic early-stage tech story: bold vision, strategic partnerships, and future-facing claims, but with a heavy reliance on forward-looking statements and little evidence of near-term operational or financial turnaround.

What the data suggests

The disclosed numbers paint a picture of a company under financial strain, with Simble reporting an increased net loss after income tax of $1,696,399 for FY25 and a cash balance of just $644,947 as of 31 December 2025. The capital raise of $2.65 million, priced at $0.005 per share, is significant relative to the company's cash position and ongoing losses, but it is earmarked for the conditional acquisition of Next Nano and does not address underlying operational cash burn. Approximately 65% of SimbleSense's cost of sales is attributed to third-party devices, highlighting the company's current dependence on external hardware and the potential margin pressure this creates. There is no disclosure of revenue, gross margin, or operating expense breakdowns, making it impossible to assess whether the company is making progress on revenue growth or cost management. The report flags a material uncertainty about going concern status, directly linking continued operations to the success of future revenue growth, cost control, and additional funding. No evidence is provided that prior targets or guidance have been met, and the absence of comparative period data further limits trend analysis. An independent analyst would conclude that, based on the numbers alone, Simble is in a precarious financial position, with high execution risk and no demonstrated improvement in core financial metrics. The data supports the existence of the research collaboration and capital raise, but not the realisation of any operational or financial benefits from these initiatives.

Analysis

The announcement presents a mix of realised actions (such as the conditional agreement to acquire Next Nano and binding commitments for a capital raise) and forward-looking aspirations (integration of nanosensor technology, margin improvement, and sector expansion). While the tone is measured and includes explicit disclosure of financial risks, several key benefits—such as improved margins, reduced hardware reliance, and expanded applications—are described as objectives or potential outcomes rather than achieved milestones. The capital outlay ($288,000 for research and $2.65 million capital raise) is significant relative to the company's small cash balance and ongoing losses, with no immediate earnings impact or quantified near-term benefits. The narrative inflates the signal by emphasizing strategic intent and future integration without supporting evidence of operational or financial improvement. The data supports the existence of the collaboration and capital raise, but not the realisation of the projected benefits.

Risk flags

• ●Going concern risk is explicitly flagged in the annual report, with ongoing losses and a low cash balance ($644,947) raising the possibility that Simble may not be able to continue operations without new funding. This is a fundamental risk for any investor, as it threatens the company's survival.
• ●High capital intensity is evident, with $288,000 committed to research and a $2.65 million capital raise required to fund the Next Nano acquisition. For a company with limited cash and negative earnings, this level of capital outlay increases dilution risk and may not yield near-term returns.
• ●The majority of the company's claims are forward-looking, including integration of nanosensor technology, margin improvement, and sector expansion. These are aspirations rather than achieved milestones, making the investment case highly speculative.
• ●Operational risk is significant, as 65% of SimbleSense's cost of sales comes from third-party devices. The company's plan to vertically integrate hardware is unproven and may face technical, supply chain, or execution hurdles.
• ●Disclosure risk is present due to the lack of key financial metrics such as revenue, gross margin, and operating expense breakdowns. This limits an investor's ability to assess the company's true financial health and progress.
• ●Pattern-based risk arises from the company's reliance on repeated capital raises and strategic announcements without evidence of operational turnaround or profitability. This could indicate a cycle of dilution and deferred execution.
• ●Timeline risk is high, as the benefits of the research collaboration and hardware integration are at least two years away, with no guarantee of commercial success. Investors face a long wait before any value realisation, during which further dilution or financial deterioration could occur.
• ●While Professor Noushin Nasiri's involvement as Macquarie Chief Investigator lends academic credibility, it does not guarantee commercial success or institutional investment. The absence of notable industry or financial backers increases the risk profile.

Bottom line

For investors, this announcement signals that Simble Solutions is doubling down on a high-risk, high-reward technology strategy while facing acute financial stress. The company's narrative is ambitious, but the evidence provided is thin: the research collaboration and capital raise are real, but the promised benefits—margin improvement, hardware integration, and sector expansion—are all speculative and years away. The explicit disclosure of going concern risk and the lack of revenue or margin data should be taken seriously, as they point to a company that may struggle to survive without further funding. Professor Noushin Nasiri's involvement adds some technical credibility, but does not change the commercial risk calculus or guarantee institutional support. To change this assessment, Simble would need to disclose concrete milestones: successful integration of nanosensor technology into its platforms, signed commercial agreements, or clear evidence of revenue and margin improvement. In the next reporting period, investors should watch for updates on the Next Nano acquisition, progress on research deliverables, and any signs of operational cash flow improvement or new commercial wins. Given the current information, this is not a signal to buy, but rather a situation to monitor closely for signs of execution or further financial deterioration. The single most important takeaway is that Simble's future hinges on its ability to turn ambitious R&D into commercial reality before its cash runs out—a bet with long odds and little margin for error.

Announcement summary

(ASX:SIS) Simble Solutions has announced a two-year co-funded research collaboration with Macquarie University to accelerate the development of its exclusive nanosensor technology, with Simble contributing $288,000 towards project-related costs over the two years. The program will focus on initial applications such as e-skin for next-generation soft robotics, UV dosimetry, and health monitoring, and aims to integrate the nanosensor technology into Simble's existing SimbleSense and CarbonView platforms. Simble entered into a conditional agreement to acquire Next Nano in December 2025, supported by binding commitments for a $2.65 million capital raise via a two-tranche placement at $0.005 per share. The FY25 annual report disclosed an increased net loss after income tax of $1,696,399 and a cash balance at 31 December 2025 of $644,947. Third-party devices represented approximately 65% of SimbleSense's cost of sales, and vertical hardware integration was seen as a way to potentially improve margins. The report flagged a material uncertainty regarding the company's ability to continue as a going concern, citing ongoing losses and liquidity considerations. The company projects that continued operations depend on revenue growth, cost management, and securing additional funding.

Disagree with this article?